MedicineNephrologyPharmacotherapyKidney TransplantationTransplant ImmunologyTransplant PharmacotherapyAcute RejectionAntibody-mediated RejectionImmunosuppression In Kidney TransplantationImmunosuppression ManagementTransplant PharmacologyTransplant RejectionAntibody-mediated Rejection TherapyBortezomib TherapyBortezomib-based TherapyKidney Transplant CareProspective Case StudyRejection ToxicityRenal Transplant RejectionTreatment Of Rejection Episodes
Here, we report our experience on three patients with AMR who were treated with bortezomib after other therapeutic interventions had failed. Bortezomib was well tolerated by two of the three patients. The third patient developed worsening thrombocytopenia following the second dose. Despite a low adverse event profile, none of the three patients conclusively responded to the bortezomib treatment. As a result of the difference in our results from that of other centers we feel that a larger prospective study is needed to define appropriate guidelines for the use of bortezomib in cases of acute rejection.
5
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Matthew J. Everly, J Everly, Brian Susskind et al. · Transplantation · 2008 · 389 citations
Abrogation of Anti-HLA Antibodies via Proteasome Inhibition
Hargovind L. Trivedi, Paul I. Terasaki, A Feroz et al. · Transplantation · 2009 · 164 citations